Cabozantinib Is Safe and Tolerable in Sorafenib-Intolerant HCC
September 16th 2023
The phase 2 ACTION trial, which evaluated the safety of second-line cabozantinib in patients with hepatocellular carcinoma who were intolerant to first-line sorafenib or who received agents other than sorafenib in the first line, did not meet its safety futility criteria, allowing the trial to continue.